38. The own experience in monitoring the late radiation reaction of criticual tissues in head and neck region  by Goleń, M. et al.
celi lung cancer. Assessed was the impact of
either treatment on the degree and duration of
relief of tumor-related symptoms and on
patient's performance status. Secondary
endpoints included treatment side-effects,
objective response and overall survival. One
hundred patients were randomly assigned to the
dose of 20 Gy/5x15 days (Arm A) or 16 Gy/2x18
days (Arm B). There were 90 men and 10
women aged between 47 and 79 (mean 66).
Eighty four patients had locally advanced tumor
and 16 patients had metastatic disease.
Squamous celi carcinoma was diagnosed in 65
patients, adenocarcinoma - in 9 patients, large
celi carcinoma - in 1 patient and unspecified
non-smali celi carcinoma - in 25 patients. Fifty
five patients were assigned to Arm A and 45 - to
Arm B. Ninety eight patients received assigned
treatment whereas twa patients died before the
end of treatment. The final results of the study
will be presented at the conference.
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MULTICENTER, RANDOMIZED
STUDY ASSESSING THE IMPACT OF
AMIFOSTINE ON NORMAL TISSUE
RADlATlON TOLERANCE DURING
HEAD AND NECK CANCER
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Oncology
A prospective, randomized multicenter study
was conducted to assess the value of amifostine
(Ethyol®) as a radioprotectant in head and neck
cancer radiotherapy. The aim of the study was
to evaluate the impact of the addition of daily
amifostine (150 mg/m2) on the degree of early
(mucositis, dysphagia, xerostomia) and late
(mucosal, cutaneous, salivary gland, mandible
and spinaj cord) radiation reactions. Assessed
were aiso patients' quality of life, local control
and overall survival. Sixty two patients fram five
Polish institutions were randomly assigned to
radiotherapy alone (Arm A - 28 patients) or
radiotherapy + amifostine (Arm B - 34 patients).
There were 43 men and 19 women. Primary
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tumor was located in the aral cavity (27
patients), oropharynx (25 patients), nasopharynx
(2 patients) and larynxlhypopharynx (8 patients).
In 43 patients radiotherapy was used as the sole
modality of tretatment and 19 patients were
irradiated postoperatively. The side effects of
amifostine were manageable. In 6 patients
amifostine intusion had to be temporarily
stopped due to hypotension and in 5 patients its
administration was permanently terminated due
to hypotension, nausea and vomiting,
septicemia or tever and visual disturbances. The
early results ot the study, tocusing on early
radiation reactions, will be presented at the
conterence.
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THE OWN EXPERIENCE IN
MONITORING THE LATE RADlATlON
REACTION OF CRITICUAL TISSUES
IN HEAD AND NECK REGION
M.Goleń\ K.Składowski\ A.Wygoda2
W.Przeorekl, B.Pilecki1 M.Sygułal,
Z. Kołosza 3
I Klinika Radioterapii1, Zakład Radioterapii2 ,
Zakład Epidemiologii3
Purpose: The estimation of scoring system
SOMA-LENT in classitication the late radiation
toxicity in patients with squamous celi cancer
irradiated in H&N region.
Material and methods:_The material includes
97 patients with orał cavity, pharyngeal and
supraglottic cancer T2•4No-1 irradited by
conventionał method (18 patients), continous
accelerated irradiation CAIR (42 patients) and
concomitant boost CB (37 patients). Total dose
was in range 66-74 Gy. The late radiation
taxicity was evaluated by SOMA-LENT system
for pharyngeal and aral cavity mucosal
membrane, skin, larynx, salivary glands, spinaj
cord. The estimation was done every
6 months after completing ot radiotherapy. In
statistical analysis the values were normalisated
to maximai intensity ot all symptoms in the
scale.
Results: The intensity ot late radiation toxicity
for mucosal membrane was increasing between
1i h-18 th month after radiotherapy and next
decreased from 24 after irradiation. For skin the
intensity of late radiation reaction increased to
24 months after treatment. For larynx we noticed
two peaks ot late radiation toxicity: between
18th_24th month and about 54 month after
irradiation. The intensity ot late radiation effect
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tor salivary glands increased to 18 month and
next diminished to 60 months. For spinaJ cord
there was observed signiticant progression ot
intensity late toxicity (mild tunctional) during
second year after irradiation.
Conclusions:
1. SOMA-LENT scale seems to be adequate in
the clinical practice tor the estimation ot late
radiation toxicity ot H&N region tissues.
2. Ongoing study has preliminary nature and is
being continued.
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PULSED DOSE RATE
BRACHYTHERAPY - DESCRIBING
OF A METHOD AND A REVIEW OF
CLlNICAL APPLlCATIONS
J. Skowronek, #T. Piotrowski,
#G. Zwierzchows·ki
I Department ot Radiotherapy, # Department ot
Physics, Greatpoland Cancer Center, Garbary
str. 15, Poznań
Introduction: Pulsed Dose Rate (POR)
treatment is a new brachytherapy modality that
combines·physical adventages ot high-dose-rate
(HDR) technology (isodose optimization,
radiation satety) with the radiobiological
adventages ot low-dose-rate (LOR)
brachytherapy.
Pulsed brachytherapy consists ot using a
stronger radiation source than tor LOR
brachytherapy and is giving a senes ot short
exposures ot 10 to 30 minutes in every hour to
approximately the same tataI dose in the same
overall as with the LOR. Modern afterloading
equipment offers some advantages over
intersitial or intracavitary insertion ot separate
needles, tubes, seeds or wires. Isodose
volumes in tissue can be created tlexibly by a
combination ot caretuJ placement ot the catheter
and adjustment ot the dwell times ot the
computerized stepping source. Automatic
removal ot the radiation sources into a shielded
sate eliminates radiation exposures to statt and
visitors. Radiation exposure is also eliminated to
the staff who tormerly loaded and unloaded a
multiplicity ot radioactive sources into the
catheters, ovoids, tubes etc.
Material and methods: This retrospective
study based on summarized clinical
investigations analyses the teasibility,
differences between methods ot brachytherapy
and preliminary oncologic results ot POR
brachytherapy.
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Since July 2000 15 patients were treated in
Greatpoland Cancer Center using POR
brachytherapy. They were 10 patients with
recurrent brain malignant glioma, 2 with
recurrent nasopharyngeal cancer, and patients
with lip cancer, recurrent breast cancer and
recurrent salivary gland cancer. Only patient
with lip cancer was treated radically. Nucietron
POR unit with 1 Ci source and PLATO planning
system were used.
Results: Short time ot observation doesn't
allow to draw a radical conclusions. On the
ground ot Iiterature and preliminary own results
it seems that POR brachytherapy is save and
efficient method ot treatmenł. The most
important compJication was a local infection in
place of implanted catheter. In some cases (tor
example in patients with recurrent malignant
glioma after teletherapy) POR brachytherapy
perhaps could be a treatment ot choice.
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COMPARISION OF TWO ACCELE-
RATED RADIOTHERAPY REGIMENS
IN MANAGEMENT OF LOCALLy
ADVANCED NON-SMALL CELL LUNG
CANCER (NSCLC) HYPER-
FRACTIONATED CONVENTIONAL
ACCELERATED RADIOTHERAPY
(RAHIP) AND ACCELERATED
CONFORMAL RADIOTHERAPY WITH
CONCURRENT BOOST (RT-BOOST)
L. Kępka*, J. Fijuth*, A. Żółciak*,
D. Blatkiewicz.#, A. Ciarcińska#
*Department ot Radiation Oncology and
#Medical Physics Department, The M.
Sklodowska-Curie Cancer Center and Institute
of Oncology. Warsaw, Poland
Background: Repopulation during radiation
therapy may compromise the results ot the
treatment ot NSCLC. In spite ot the data
showing an improvement ot therapeutic ratio
with shortening ot the total treatment time, there
is no univoque way ot doing ił. Current study
was conducted to compare two different
regimens ot accelerated radiotherapy.
Material/Methods: From March 1999 to
November 2000 torty patients with stage III
NSCLC were included. Twenty-eight pts. (70%)
received 3-4 cycles ot induction chemotherapy
(cis-platinum, vepeside). Twenty-six p. were
treated according to RAHIP schema, 14 pts.
according to RT-BOOST schedule. RAHIP
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